Feature|Articles|November 20, 2026

The Next Evolution of Patient-Centered Trials Starts with Design

Listen
0:00 / 0:00

Key Takeaways

  • Decentralization is shifting from a default strategy to fit-for-purpose delivery decisions that optimize patient burden, site sustainability, clinical oversight, and endpoint integrity.
  • Patient intelligence methods provide evidence to map likely barriers to specific protocol activities, informing targeted supports such as education, scheduling changes, remote services, or site-based interactions.
SHOW MORE

Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.

“The future of patient-centered delivery lies in designing experiences that combine the flexibility of digital tools with the guidance and support participants need to successfully navigate research.”

The clinical research industry has spent much of the post-pandemic era expanding decentralized and hybrid trial capabilities. Remote visits, telehealth, home health services, eConsent, and digital engagement platforms are now well-established components of modern trial delivery.

As a result, the conversation has shifted. The question is no longer whether decentralized approaches can work, but how they should be applied. Clinical trial sponsors are moving beyond a one-size-fits-all view of decentralization and focusing on how to match delivery models to the realities of patients, caregivers, and clinical trial sites.

The next phase of decentralized clinical trials is less about adoption and more about participation-model design. Sponsors are increasingly using patient experience, protocol requirements, and intentional operational planning to determine where flexibility reduces burden and risk; where site-based delivery remains essential; and how each choice supports participants, sites, and endpoint integrity.

From assumptions to patient intelligence

One of the most significant shifts in patient-centered trial design has been the move from assumptions to evidence.

Modern patient-centered trial design increasingly relies on a combination of patient intelligence approaches rather than a single source of feedback. Patient personas, interviews, surveys, advocacy group engagement, and empathy mapping can each provide different perspectives on the participant experience. Together, these methods help sponsors understand not only who potential participants are, but how they think about research, what concerns influence their decisions, and where practical barriers may emerge throughout the study journey.

For example, patient personas may reveal that two participants with the same condition face entirely different participation challenges. One may be primarily concerned about lengthy travel requirements, while another may be balancing caregiver responsibilities and work schedules, or be uncertain about using digital tools. Empathy mapping adds another layer of understanding by helping study teams explore what participants are thinking, feeling, hearing, and experiencing as they consider or progress through a trial.

When combined, these insights provide a more complete picture of the participant experience, allowing sponsors to design visit schedules, support services, communication strategies, and delivery models around real-world needs instead of assumptions.

More importantly, these insights give sponsors a practical basis for making delivery decisions. Rather than assuming all participants benefit from the same level of flexibility, study teams can map patient needs and likely friction points to specific protocol touchpoints. These insights can then help determine where education, scheduling changes, remote services, human support, or site-based interactions are most likely to improve participation and retention.

Across 12 recent decentralized studies, study teams reported consistent reductions in dropout rates. While results will differ across protocols and delivery models, the observed reductions in dropout emphasize the value of designing participation strategies around anticipated barriers instead of retrofitting solutions once those barriers become visible.

Designing around real-world participation

Patient needs are critical, but they are only one part of the design equation. Effective patient-centered delivery requires balancing participant realities with site readiness, protocol complexity, country feasibility, clinical oversight, data flow, and regional requirements so that flexibility does not come at the expense of site sustainability, safety, or data integrity.

What has become increasingly clear is that burden is often highly individual. The same protocol that appears manageable on paper may create very different experiences for different participant populations.

This is where design-first planning becomes essential. Instead of defaulting to either a traditional site-based model or a highly decentralized approach, sponsors are increasingly asking a series of practical questions:

  • Which procedures are critical to quality and clinical oversight, and therefore best conducted at the research site?
  • Which lower-risk activities can be completed remotely, in the home or through local providers?
  • Where might additional patient education, human support or digital tools reduce participation burden?
  • How can these decisions improve the participant experience while maintaining study integrity?

Depending on the protocol, study design may include telehealth between site visits, home-based clinical services, direct-to-patient logistics, concierge travel support, local healthcare providers, and/or targeted digital engagement, all within a clearly governed operating model.

The goal is no longer to move activities away from the site whenever possible. It is to determine where each activity can be completed most effectively. In obesity research, this may mean combining site-based assessments with telehealth interactions, digital engagement tools, and in-home dietitian support between visits. Other protocols may require a very different balance.

In one recent global obesity and cardiovascular-risk-management study, a hybrid delivery approach helped complete enrollment eight months ahead of schedule while supporting the recruitment of 5,400 participants across 35 countries. Rather than demonstrating the value of any single decentralized capability, results like these illustrate the potential of aligning delivery models more closely with participant and protocol needs.

Access begins before recruitment

Access is often discussed as a recruitment challenge, but many participation barriers emerge long before recruitment begins. As a result, sponsors are increasingly asking a more fundamental question: Does the trial experience reflect the realities of the people it hopes to enroll?

Site placement, visit schedules, transportation support, community outreach, digital engagement strategies, and participant communications can all influence who can realistically participate in research. Community-based omnichannel engagement programs have demonstrated how aligning trial outreach and delivery with participant preferences can expand participation, with one recent initiative engaging 37% of participants from traditionally underrepresented populations.

Technology to support the experience, not define it

Technology remains an important enabler of patient-centered research, but it should be configured around the intended participant experience and not treated as the strategy itself. Telehealth, eConsent, ePROs, wearable devices, reminders, and engagement platforms can simplify participation and create flexibility when they are aligned with protocol expectations, site workflows, support pathways, and country feasibility.

However, the most successful patient-centered programs recognize that technology is only one driver of an enhanced participant experience. Digital tools may facilitate participation, but trusted human interactions often determine whether participants remain engaged over the duration of a DCT or hybrid trial.

Participants often need personalized support, clear education and practical guidance throughout their study journey. Coordinators, patient navigators, remote research clinicians, support centers, and site teams all play a critical role in helping participants understand expectations, complete study activities, and stay engaged. In one decentralized rare disease study model, patients achieved 97% eDiary compliance, illustrating how connected digital workflows and human support can work together to sustain participation over time.

The future of patient-centered delivery lies in designing experiences that combine the flexibility of digital tools with the guidance and support participants need to successfully navigate research.

The next phase of DCTs: Precision in design

The industry's early DCT efforts focused on proving that research could occur beyond the walls of the site. The next chapter will focus on determining when, where and for whom those approaches create the greatest value.

Sponsors who bring patient intelligence and participation strategy forward and then connect them to site enablement, flexible delivery, coordinated digital orchestration, and measurable outcomes will be better positioned to reduce delivery risk and execute studies with greater confidence.

Ultimately, success will not be measured by how decentralized a trial becomes, but by whether the participation model makes the study more feasible for patients and sites, protects data quality and oversight and delivers measurable value for sponsors.

About the author

A clinician-turned-life sciences executive, Sinéad Callinan is head of patient-centered delivery at IQVIA, where she helps organizations design and deliver more accessible and participant-focused clinical trials.

With more than two decades of experience spanning clinical practice, research operations, and digital transformation, she specializes in decentralized and hybrid research models, digital innovation, and operational approaches that improve patient and site experience. Sinéad champions governance models that strengthen compliance while improving the human experience of participating in research.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© putilov_denis - © putilov_denis - stock.adobe.com
Sponsors rigorously vet CROs for oncology expertise but rarely apply the same scrutiny to the IRB reviewing their trials, even though increasingly complex protocols require reviewers with substantive therapeutic knowledge, not just a rostered oncologist.